• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    3/12/25 8:40:30 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    false 0000926326 0000926326 2025-03-12 2025-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C.  20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
    1934

     

    Date of Report (Date of earliest event reported): March 12, 2025

     

    OMNICELL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   000-33043   94-3166458
    (State or other jurisdiction of
    incorporation)
     

    (Commission File Number)

     

    (IRS Employer Identification Number)

     

    4220 North Freeway

    Fort Worth, TX 76137

    (Address of principal executive offices, including zip code)

     

    (877) 415-9990

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading Symbol  Name of each exchange on which registered
    Common Stock, $0.001 par value  OMCL  NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On March 12, 2025, Omnicell, Inc. (the “Company”) announced that Nchacha Etta will step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named. Pending his departure, Mr. Etta will continue to serve as Executive Vice President, Chief Financial Officer while the Company searches for a new Chief Financial Officer and will assist with the transition of his role and responsibilities.

     

    In connection with Mr. Etta’s departure, it is expected that the Company and Mr. Etta will enter into a transition agreement, the material terms of which have not been finalized as of the date of this Current Report on Form 8-K.

     

    The departure of Mr. Etta is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices (financial reporting, accounting or otherwise).

     

    The Company would like to thank Mr. Etta for his contributions to the Company throughout his employment, and for playing an important role in the Company’s growth.

     

    Item 7.01 Regulation FD Disclosure.

     

    On March 12, 2025, the Company issued a press release reiterating its first quarter and full year 2025 guidance. A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit 
    Number
      Exhibit Description
         
    99.1   Press release entitled “Omnicell Announces Chief Financial Officer Transition” dated March 12, 2025
         
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      OMNICELL, INC.
       
    Date: March 12, 2025 /s/ Corey J. Manley
      Corey J. Manley
      Executive Vice President and Chief Legal and Administrative Officer

     

     

    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    SEC Filings

    See more
    • SEC Form S-8 filed by Omnicell Inc.

      S-8 - OMNICELL, INC. (0000926326) (Filer)

      6/18/25 4:04:58 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      6/5/25 5:13:20 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/23/25 4:34:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

      Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

      5/22/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces New Products for Perioperative and Clinic Settings

      RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical

      5/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Opens New Innovation Lab in Austin, Texas

      Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey Omnicell, Inc. (NASDAQ:OMCL), ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry. As hospitals and health systems are grappling with rising costs and staffing shortages, we believe that innovative automated technologies will be imp

      5/14/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:57 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:11 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/3/25 4:12:37 PM ET
      $OMCL
      Computer Manufacturing
      Technology